Cart
sales@molnova.com
Tyrphostin A1
CAS No. 2826-26-8
Tyrphostin A1( Tyrphostin 1 | AG9 )
Catalog No. M20945 CAS No. 2826-26-8
Tyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 50 | In Stock |
|
| 50MG | 71 | In Stock |
|
| 100MG | 91 | In Stock |
|
| 200MG | 133 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTyrphostin A1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
-
DescriptionTyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
-
In Vitro——
-
In Vivo——
-
SynonymsTyrphostin 1 | AG9
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2826-26-8
-
Formula Weight184.19
-
Molecular FormulaC11H8N2O
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (542.92 mM)
-
SMILESCOc1ccc(C=C(C#N)C#N)cc1
-
Chemical Name2-[(4-Methoxyphenyl)methylidene]propanedinitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Du C Bright J J Sriram S . Inhibition of CD40 signaling pathway by tyrphostin A1 reduces secretion of IL-12 in macrophage Th1 cell development and experimental allergic encephalomyelitis in SJL/J mice[J]. Journal of Neuroimmunology 2001 114(1-2):69-79.
molnova catalog
related products
-
AG-825
AG-825（Tyrphostin C15） is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (Tyrphostin C15) inhibits HER2 and shows anticancer activity in a mouse xenograft model of breast cancer.
-
PF-06459988
PF-06459988 (PF06459988, PF 6459988) is a potent, selective, irreversible EGFR mutants with IC50 of 13, 7, 21 and 90 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.
-
Falnidamol
Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. It displays >1000-fold lower potency against ErbB2 (IC50=3.4 μM) and other related tyrosine kinases (IC50>10 μM).
